Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 2002

1.

Clinical commentary on "Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab".

Salmen A.

Mult Scler. 2017 Jun 1:1352458517717810. doi: 10.1177/1352458517717810. [Epub ahead of print] No abstract available.

PMID:
28643548
2.

Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.

Mulero P, Auger C, Parolin L, Fonseca E, Requena M, Rio J, Tintoré M, Rovira A, Montalban X.

Mult Scler. 2017 Jun 1:1352458517711569. doi: 10.1177/1352458517711569. [Epub ahead of print]

PMID:
28643544
3.

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS.

Gahlen A, Trampe AK, Haupeltshofer S, Ringelstein M, Aktas O, Berthele A, Wildemann B, Gold R, Jarius S, Kleiter I.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e363. doi: 10.1212/NXI.0000000000000363. eCollection 2017 Jul.

PMID:
28642888
4.

Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.

Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, Mozley PD, Riley CS, Newman SM, Gauthier SA.

Mult Scler Relat Disord. 2017 Jul;15:27-33. doi: 10.1016/j.msard.2017.04.008. Epub 2017 Apr 29.

PMID:
28641769
5.

Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.

Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L.

Expert Opin Drug Saf. 2017 Jun 22. doi: 10.1080/14740338.2017.1346082. [Epub ahead of print]

PMID:
28641055
6.

Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.

Foley RW, Tagg NT, Schindler MK, Fenton KM, Reich DS, Cortese I, Mowry EM.

Mult Scler. 2017 Jun 1:1352458517702533. doi: 10.1177/1352458517702533. [Epub ahead of print]

PMID:
28639536
7.

Clinical commentary on 'Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis', by Foley et al.

Chan A.

Mult Scler. 2017 Jun 1:1352458517712868. doi: 10.1177/1352458517712868. [Epub ahead of print]

PMID:
28639492
8.

[A prospective, open, non-randomized study on the safety and efficacy of natalizumab (tisabri) in the Russian population of patients with relapsing-remitting multiple sclerosis].

Boyko AN, Evdoshenko EP, Vorob'eva OV, You X, Pukaite V.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(8. Vyp. 2):25-35. doi: 10.17116/jnevro20151158225-35. Russian.

PMID:
28635712
9.

Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).

Sabol RA, Noxon V, Sartor O, Berger JR, Qureshi Z, Raisch DW, Norris LB, Yarnold PR, Georgantopoulos P, Hrushesky WJ, Bobolts L, Ray P, Lebby A, Kane RC, Bennett CL.

Cancer Med. 2017 Jun 20. doi: 10.1002/cam4.1098. [Epub ahead of print]

10.

Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes.

Kantorová E, Bittšanský M, Sivák Š, Baranovičová E, Hnilicová P, Nosáľ V, Čierny D, Zeleňák K, Brück W, Kurča E.

BMC Cancer. 2017 Jun 19;17(1):424. doi: 10.1186/s12885-017-3415-1.

11.

Tumefactive demyelinating lesions: A comprehensive review.

Algahtani H, Shirah B, Alassiri A.

Mult Scler Relat Disord. 2017 May;14:72-79. doi: 10.1016/j.msard.2017.04.003. Epub 2017 Apr 9. Review.

PMID:
28619436
12.

[Immune reconstitution inflammatory syndrome and rebound syndrome in multiple sclerosis patients who stopped disease modification therapy: current understanding and a case report].

Belova AN, Rasteryaeva MV, Zhulina NI, Belova EM, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2. Vyp. 2):74-84. doi: 10.17116/jnevro20171172274-84. Russian.

PMID:
28617365
13.

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.

Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C.

Neurol Neuroimmunol Neuroinflamm. 2017 Apr 14;4(3):e346. doi: 10.1212/NXI.0000000000000346. eCollection 2017 May.

14.

Cognitive evolution in natalizumab-treated multiple sclerosis patients.

Jacques FH, Harel BT, Schembri AJ, Paquette C, Bilodeau B, Kalinowski P, Roy R.

Mult Scler J Exp Transl Clin. 2016 Jun 7;2:2055217316657116. doi: 10.1177/2055217316657116. eCollection 2016 Jan-Dec.

15.

CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.

Carotenuto A, Scalia G, Ausiello F, Moccia M, Russo CV, Saccà F, De Rosa A, Criscuolo C, Del Vecchio L, Brescia Morra V, Lanzillo R.

J Neuroimmunol. 2017 Aug 15;309:47-50. doi: 10.1016/j.jneuroim.2017.05.006. Epub 2017 May 12.

PMID:
28601287
16.

Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan.

Nobile-Orazio E, Gallia F, Terenghi F, Bianco M.

Expert Rev Neurother. 2017 Jun 9. doi: 10.1080/14737175.2017.1340832. [Epub ahead of print]

PMID:
28597710
17.

Clinical and radiological control of highly active relapsing-remitting multiple sclerosis with first-line natalizumab.

Meca-Lallana JE, Carreón-Guarnizo E, Hernández-Clares R, García-Molina E, Díaz-Pérez J, Leon-Hernández A, Zamarro-Parra J, Martín-Fernández JJ.

Neurodegener Dis Manag. 2017 Jun 8. doi: 10.2217/nmt-2017-0007. [Epub ahead of print]

PMID:
28592169
18.

Quantification of γδ T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment.

Paužuolis M, Eich T, Burman J.

PLoS One. 2017 Jun 6;12(6):e0179095. doi: 10.1371/journal.pone.0179095. eCollection 2017.

19.

Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?

Scarpazza C, Prosperini L, Mancinelli CR, De Rossi N, Lugaresi A, Capobianco M, Moiola L, Naldi P, Imberti L, Gerevini S, Capra R.

J Neurol Sci. 2017 Jul 15;378:233-237. doi: 10.1016/j.jns.2017.05.018. Epub 2017 May 12.

PMID:
28566170
20.

Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay.

Schultz HS, Reedtz-Runge SL, Bäckström BT, Lamberth K, Pedersen CR, Kvarnhammar AM; ABIRISK consortium.

PLoS One. 2017 May 31;12(5):e0178544. doi: 10.1371/journal.pone.0178544. eCollection 2017.

Supplemental Content

Loading ...
Support Center